| Followers | 60 |
| Posts | 11411 |
| Boards Moderated | 0 |
| Alias Born | 01/31/2008 |
Sunday, July 11, 2021 9:11:21 AM
I have yet to read anything that says Leronlimab is "good science"?!?
In contrast and in reference to a company we both follow, the compound Blarcamesine has had a string of positive FDA trials in multiple indications, with very conservative management. I like that combination much more than no trial evidence and corporate sponsored hype.
Well the same was said about blarcamesine until the recent Rett and PDD results. Making big money in biotech requires a bit of faith on thin evidence, whether LL now or B in 2015 when I loaded the truck. Much prefer to buy in under $2 than at $25.
That is where Management is key. Well run ship keeping cash burn and dilution low is critical. Competence in execution is critical. remaining focused on the objective is critical. CYDY mgt has none of these traits, and I should not have invested in it. Only did to diversify, which is a problem since finding other biotechs with good mgt and good science at less than sky high prices is hard.
In contrast and in reference to a company we both follow, the compound Blarcamesine has had a string of positive FDA trials in multiple indications, with very conservative management. I like that combination much more than no trial evidence and corporate sponsored hype.
Well the same was said about blarcamesine until the recent Rett and PDD results. Making big money in biotech requires a bit of faith on thin evidence, whether LL now or B in 2015 when I loaded the truck. Much prefer to buy in under $2 than at $25.
That is where Management is key. Well run ship keeping cash burn and dilution low is critical. Competence in execution is critical. remaining focused on the objective is critical. CYDY mgt has none of these traits, and I should not have invested in it. Only did to diversify, which is a problem since finding other biotechs with good mgt and good science at less than sky high prices is hard.
Recent CYDY News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/21/2026 04:15:12 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/20/2026 09:08:39 PM
- CytoDyn to Present at the LD Micro Invitational XVI • GlobeNewswire Inc. • 05/15/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
